SLC5A2 and peripheral arterial disease: By reducing blood pressure, improving endothelial function, and exerting anti-inflammatory effects, SGLT2-i could slow the progression of ATS in PAD, reducing the incidence of stenosis, critical limb ischemia, and the need for revascularization procedures.